Get the Stockscreener App
5.36
3.25%
-0.18
After Hours:
5.46
0.10
+1.87%
Bicycle Therapeutics Plc Adr stock is traded at $5.36, with a volume of 258.40K.
It is down -3.25% in the last 24 hours and down -18.54% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$5.54
Open:
$5.58
24h Volume:
258.40K
Relative Volume:
0.83
Market Cap:
$371.81M
Revenue:
$28.31M
Net Income/Loss:
$-250.99M
P/E Ratio:
-1.478
EPS:
-3.6266
Net Cash Flow:
$-242.07M
1W Performance:
+0.94%
1M Performance:
-18.54%
6M Performance:
-25.76%
1Y Performance:
-56.49%
1-Day Range:
$5.18
$5.59
1-Week Range:
$5.18
$5.95
52-Week Range:
$5.18
$13.11
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
5.36 | 384.30M | 28.31M | -250.99M | -242.07M | -3.6266 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Hold |
| Oct-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-08-24 | Initiated | Stephens | Equal-Weight |
| Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Aug-31-22 | Initiated | Cowen | Outperform |
| Jul-28-22 | Initiated | Barclays | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | SVB Leerink | Outperform |
| Dec-09-21 | Initiated | Needham | Buy |
| Sep-30-21 | Initiated | B. Riley Securities | Buy |
| Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-20 | Initiated | Oppenheimer | Outperform |
| Apr-17-20 | Initiated | H.C. Wainwright | Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
| Jun-17-19 | Initiated | Canaccord Genuity | Buy |
| Jun-17-19 | Initiated | Goldman | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
| Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6%Time to Sell? - MarketBeat
Bicycle Therapeutics announces leadership changes for next phase By Investing.com - Investing.com South Africa
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com South Africa
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 - ChartMill
Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $70,210.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Operating cash flow per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView — Track All Markets
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-12-28 | Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Investors to Connect - ACCESS Newswire
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-24 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Connect - ACCESS Newswire
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - WV News
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages - Defense World
45,950 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Purchased by Dynamic Technology Lab Private Ltd - MarketBeat
Jefferies Financial Group Inc. Boosts Stock Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Coverage Initiated by Analysts at Truist Financial - Defense World
Total revenue of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Preferred dividends of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Truist Securities initiates coverage on Bicycle Therapeutics stock with Hold rating - Investing.com UK
Investigation Alert: Bicycle Therapeutics plc (BCYC) Under ScrutinyContact Levi & Korsinsky for Details - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - MarketScreener
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
A new trading data show Bicycle Therapeutics Plc ADR (BCYC) is showing positive returns. - setenews.com
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 8.8% Following Analyst Downgrade - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 8.8% After Analyst Downgrade - Defense World
Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat
EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat
Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa
RBC Capital downgrades Bicycle Therapeutics stock on delayed pipeline progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com South Africa
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Placera.se
Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 5.2%Here's Why - MarketBeat
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):